Crescent Biopharma said it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year. It plans to start the first of multiple Phase III studies in early 2028.
CBIO · Crescent Biopharma, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028.
Crescent Biopharma completed Phase 1/2 ASCEND dose escalation after dosing more than 125 patients and plans initial CR-001 monotherapy data in Q1 2027. Cash was $289.4 million as of September 30, 2026, funding operations into the second half of 2028.
Crescent Biopharma, Inc. initiated the global Phase 1/2 APOLLO trial in the fourth quarter of 2026 and reported a nine-month net loss of $85.8 million. Cash was $289.4 million as of September 30, 2026.
Crescent Bio plans Q1-2027 safety and tolerability data from 125-plus CR001 monotherapy patients, plus ORR results for up to 12 frontline non-small cell lung cancer patients against a 50 percent benchmark.
Crescent plans Q1-2027 CR001 monotherapy data and a first phase three study in early 2028.
Crescent Biopharma began ASCEND chemotherapy-combination enrollment, plans additional ADC combination studies, received IND allowance for CR-002, and expects APOLLO initiation in the fourth quarter of 2026 and initial data in the second half of 2027.